This announcement is a separate document:
中國抗體-B：截至二零二三年十二月三十一日止年度全年業績公告；更改所得款項用途；建議修訂二零二二年購股權計劃；及建議更新計劃授權限額及服務提供商分項限額
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023;CHANGE IN USE OF PROCEEDS;PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; ANDPROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.